Marshall Wace
Marshall Wace is an investment firm with over $22 billion in assets under management.
Business Model:
Revenue: $25M
Employees: 201-500
Rankings
Industries / Tags:
Detailed Marshall Wace Information
Geographic Data
Address: George House, 131 Sloane Street
City: London
State: england
Zip: SW1X 9AT
Country: GB
Financial Info
Stage:
Raised Last:
$0
Raised Total:$21M
Social
Twitter
Linkedin
Crunchbase
Metrics
1,900,932Website Global Rank
11,444Website Monthly Traffic
Twitter Followers
Description
Founded in 1997, Marshall Wace is a hedge fund manager specializing in global long/short equity. The firm has investment management offices in London; New York; and Hong Kong. Marshall Wace LLP was named Management Firm of the Year by the EuroHedge Awards 2011, reflecting the strong performance delivered by a number of our funds during the year. The firm is dedicated to the objective of providing its clients with a persistent, risk-adjusted return on their investment. Through a range of products, investors can select funds offering variable sources of alpha and beta, in different combinations, from equity markets around the world. Marshall Wace brings together two distinct but complementary approaches to asset management. First, traditional, fundamental long/short investing grounded in stock-specific analytical research, and secondly, Marshall Wace TOPS (‘MW TOPS’), the pioneering, and proprietary, systematic, alpha capture strategy.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2022 | ConsenSys | Series D | 0 |
| 5/2021 | Pine Labs | Venture Round | 0 |
| 4/2022 | Circle | Private Equity Round | 0 |
| 12/2022 | Karyopharm Therapeutics | Post-IPO Equity | 0 |
| 9/2022 | 21.co | Equity | 25M |
| 4/2022 | Turtlemint | Series E | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 3/2021 | Flywire | Series F | 60M |
| 3/2021 | Century Therapeutics | Series C | 0 |
| 10/2021 | CRED | Series E | 251M |
| 9/2022 | ACELYRIN | Series C | 0 |
| 11/2021 | ACELYRIN | Series B | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 11/2022 | TRM Labs | Series B | 0 |
| 4/2021 | Exscientia | Series D | 225M |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 11/2021 | Vayana Network | Series C | 0 |
| 1/2022 | Metagenomi | Series B | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 9/2021 | Varo Money | Series E | 0 |
| 5/2021 | Circle | Venture Round | 0 |
| 9/2022 | Neurolens | Venture Round | 67.6M |
| 6/2022 | Elektrofi | Series B | 0 |
| 2/2022 | Parse Biosciences | Series B | 0 |
| 1/2022 | Accelerant | Private Equity Round | 0 |
| 11/2021 | ConsenSys | Series C | 0 |
| 12/2021 | TRM Labs | Series B | 0 |
| 10/2020 | International Airlines Group (IAG) | Post-IPO Equity | 182.2M |
| 1/2022 | Lukka | Series E | 0 |
| 9/2020 | LGI Homes | Post-IPO Equity | 1.5M |
| 4/2021 | Forge Biologics | Series B | 120M |
| 12/2021 | Tipalti | Series F | 0 |
| 8/2021 | Neurogastrx | Series B | 60M |
| 6/2022 | Elektrofi | Series B | 0 |
| 4/2022 | Turtlemint | Series E | 0 |
| 4/2022 | Circle | Private Equity Round | 0 |
| 2/2022 | Parse Biosciences | Series B | 0 |
| 2/2022 | ConsenSys | Series D | 0 |
| 1/2022 | Metagenomi | Series B | 0 |
| 1/2022 | Lukka | Series E | 0 |
| 1/2022 | Accelerant | Private Equity Round | 0 |
| 12/2021 | Tipalti | Series F | 0 |
| 12/2021 | TRM Labs | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
